Device for enteral CO2 absorption, as well as corresponding assembly

ES3084337T3Undetermined Publication Date: 2026-11-12O11 BIOMEDICAL GMBH (100 00)
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
ES2024801491T
Authority / Receiving Office
ES · ES
Patent Type
Patents
Current Assignee / Owner
Priority Date
2023-11-03
Filing Date
2024-11-04
Publication Date
2026-11-12
Estimated Expiration
2044-11-04

AI Technical Summary

Technical Problem

Existing treatments for hypercapnia, such as mechanical ventilation, are equipment-intensive, costly, and risky, while alternative methods like oral CO₂ absorbers are not effective enough.

Method used

A catheter with a gas-permeable membrane and CO₂-absorbing carrier medium is designed for enteral CO₂ absorption in the intestinal tract, allowing controlled CO₂ removal through a selectively permeable membrane that prevents carrier medium release and maintains intestinal balance.

Benefits of technology

The catheter enables rapid and large-scale CO₂ removal with minimal side effects, suitable for intensive care and high-risk patients, without impairing the respiratory tract, and can be adjusted to individual patient needs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000017_0000
    Figure 00000017_0000
  • Figure 00000018_0000
    Figure 00000018_0000
  • Figure 00000019_0000
    Figure 00000019_0000
Patent Text Reader

Abstract

The invention relates to a device for the controlled in vivo absorption of CO2, comprising a catheter with a gas-permeable membrane and a CO2-absorbing carrier medium. The invention also relates to an assembly including such a device and its use in the prophylaxis or treatment of respiratory system diseases, or for the induction of hypercapnia in a patient.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] The present invention relates to a device for controlled in The invention relates to a device for the in vivo uptake of CO₂ comprising a catheter for use in the intestinal tract, having a gas-permeable membrane and a CO₂-absorbing carrier medium. The invention further relates to a set comprising this device. The invention also relates to the device or set being suitable for use in the prophylaxis or treatment of diseases of the respiratory system or for use in inducing hypocapnia in a patient. Background of the invention

[0002] Numerous respiratory diseases are associated with elevated blood CO2 levels, a condition also known as hypercapnia. Hypercapnia is usually caused by impaired lung ventilation (formerly called global respiratory failure), resulting from alveolar hypoventilation or respiratory pump failure. Hypercapnic respiratory failure can occur, for example, during a worsening of chronic obstructive pulmonary disease (COPD). However, hypercapnia can also result from metabolic alkalosis or from inhaling air with high carbon dioxide concentrations (carbon dioxide poisoning occurs at concentrations of 8 to 10% by volume). Medical professionals also refer to this as hypercapnic respiratory failure, meaning carbon dioxide poisoning accompanied by low blood oxygen levels. Typical symptoms of hypercapnia include shortness of breath, restlessness, drowsiness, headache, confusion, cyanosis (bluish discoloration of the skin), and an elevated heart rate.

[0003] To treat hypercapnic respiratory failure, mechanical ventilation, such as pressure-supported non-invasive ventilation, can be used to support the patient's breathing. This treatment is equipment-intensive and costly, and carries numerous risks, including pressure-induced lung damage, pneumonia, increased chest pressure, and worsening of heart failure. Furthermore, this treatment is extremely taxing on the patient.

[0004] However, hypercapnia can also occur during intensive care treatment of children and adults when increased CO2 partial pressures are accepted in favor of gentler ventilation (also known as "permissive hypercapnia").

[0005] Therefore, there is a need for alternative methods to treat hypercapnia. For example, there are experimental approaches to reduce blood CO₂ levels by orally administering CO₂ absorbers, utilizing the large internal surface area of ​​the human digestive tract. US 2022 / 0040393 A1 discloses a prior art device.

[0006] WO 2020 / 035163 A1 discloses a composition comprising a CO₂ absorber or adsorbent with a polymeric coating of a silicone rubber produced from liquid silicone rubber or with a polymeric coating of a cellulose derivative. It teaches the rubber coating process by dip coating with liquid silicone rubber and subsequent compression into tablets.

[0007] WO 2020 / 035163 A1 discloses the encapsulation of a powdered CO2 absorber in a capsule made of regenerated cellulose.

[0008] Further state of the art can be found in WO 2005 / 097075 A2, US 2015 / 245999 A1, US 2017 / 319617 A1 or WO 2023 / 072929 A1.

[0009] The present invention is based on the objective of improving the state of the art or offering an alternative. Summary of the invention

[0010] According to a first aspect of the present invention, the stated problem is solved by a device for the enteral absorption of CO2, comprising a catheter for use in the intestinal tract, wherein the catheter comprising an inlet and an outlet for a CO2-absorbing carrier medium and a gas-permeable membrane, wherein: o the membrane defines a lumen for receiving the CO2-absorbing carrier medium, o a first, inner side of the membrane is directed towards the lumen so that it is in contact with the carrier medium when the lumen is filled with the CO2-absorbing carrier medium, and o a second, outer side of the membrane is directed towards an environment so that it is in contact with the intestinal environment when positioned in an intestine, o the membrane has a gas passage from the outer to the inner side so that, when positioned in the intestinal environment, the membrane allows the diffusion of gas from the intestinal tract into the CO2-absorbing carrier medium, and wherein the catheter is used for the application of CO 2 -receiving carrier medium or with the CO 2 -receiving carrier medium is filled.

[0011] Further embodiments are the subject of the further independent and dependent claims.

[0012] The following definition should be explained in this context: Within the scope of the present invention, a "catheter" is understood to be a flexible device that can be inserted into the body via a body opening and has connections for introducing and draining a preferably liquid carrier medium.

[0013] The catheter is designed for use with the CO₂-absorbing carrier medium, insofar as it is filled with the CO₂-absorbing carrier medium during therapeutic application and allows for the exchange of CO₂-containing carrier medium with fresh carrier medium via the inlet and outlet. In one embodiment, the catheter is filled with the CO₂-absorbing carrier medium.

[0014] The catheter according to the invention is designed for use in the intestinal tract and is therefore adapted in size and design to the intestinal tract. It is accordingly inserted rectally through the anus and positioned in the lumen of the intestine. Preferably, it is positioned in the Descending colon and / or in sigmoid colon positioned, that is, between the Flexura coli sinestra and the rectum.

[0015] The intestinal environment refers to the environment surrounding the catheter positioned in the intestinal tract. This includes the lumen of the intestinal tract and, in the case of a catheter that (even if only temporarily) makes contact with the intestinal wall with at least part of its membrane, also the intestinal wall itself as CO2-containing tissue.

[0016] The invention has several advantages over the prior art.

[0017] The catheter with its surrounding membrane allows large quantities of CO₂-absorbing medium to be delivered to the body. Combined with the large surface area of ​​the rectum / colon, this enables the rapid removal of significant amounts of CO₂ from the body, making the catheter particularly suitable for treating intensive care and high-risk patients.

[0018] The complete encapsulation with the membrane provides a closed and secure enclosure, allowing the use of a wide range of CO2-absorbing carrier media, and enabling the safe use of media that may have side effects.

[0019] By combining several parameters, such as the choice of CO₂ carrier medium, its concentration, and the flow rate, a person skilled in the art can specifically adapt the device according to the invention to the respective therapeutic purpose. Furthermore, changing the flow rate of the carrier medium allows for targeted adjustment to the patient's needs and can even be carried out within a single treatment session.

[0020] The catheter design is suitable for large-scale production.

[0021] Due to its enteral administration, the present device with the catheter can be widely used for the treatment of respiratory diseases without impairing or burdening the respiratory tract.

[0022] This results in an innovative and low-side-effect therapy option that can be used especially in intensive care patients or high-risk patients. The invention in detail

[0023] According to the invention, the catheter has an inlet and an outlet for a CO2-absorbing carrier medium, wherein these are two separate access points.

[0024] In an alternative embodiment, which is not part of the claimed invention, the inlet can also function as an outlet. In this embodiment, the CO₂-absorbing carrier medium can be introduced into the catheter through the access point in a first step, and then, after absorbing CO₂, it can be extracted from the catheter through the same access point.

[0025] According to the claimed invention, the CO2-absorbing carrier medium is a liquid in which a CO2-absorbing substance is dispersed.

[0026] Advantageously, in the device according to the invention, the gas-permeable membrane can be provided to be impermeable to water and / or have a "Molecular weight cutoff" (MWCO) of less than 200 Daltons.

[0027] A water-impermeable membrane prevents the diffusion of water molecules from the intestine into the catheter and vice versa, thus maintaining the water balance of the intestine and preventing possible constipation or diarrhea.

[0028] In one embodiment, the gas-permeable membrane is also impermeable to water vapor. When using a liquid carrier medium, moistening the carrier medium is not necessary.

[0029] In the context of this application, the term "water impermeability" is synonymous with the term "water tightness." The so-called water tightness of the gas-permeable membrane is measured by the water column pressure at which the material begins to allow water to pass through. According to DIN standard EN 343:2019-06, a membrane is considered water impermeable from a pressure of 1,300 mm upwards.

[0030] In a preferred embodiment, the gas-permeable membrane of the catheter is designed such that during the in In vivo application, the release of the CO₂-absorbing carrier medium or the CO₂ absorber is essentially prevented. "Essentially" here means that during the in During vivo application of the catheter, at most 5 wt.%, preferably at most 4 wt.%, preferably at most 3 wt.%, further preferably at most 1 wt.% of the CO2-absorbing carrier medium or the CO2 absorber is released from the catheter.

[0031] Many CO₂-absorbing carrier media or CO₂ absorbers lead to undesirable side effects when released in the gastrointestinal tract. With calcium hydroxide, a strong base, the release would cause a significant increase in pH. With magnesium hydroxide, excessive release could lead to muscle weakness and diarrhea.

[0032] According to the invention, the CO₂-absorbing catheter is a device that serves exclusively for the absorption of CO₂ from the organism. The release of the CO₂-absorbing carrier medium or the CO₂ absorber, whether as a CO₂-free reactant or a CO₂-containing product, is to be prevented as far as possible. In this sense, the gas-permeable membrane of the catheter is a semipermeable or selectively permeable barrier that allows CO₂ to pass through from the organism to permit absorption by the CO₂ absorber inside the catheter, but is impermeable to the CO₂ absorber and preferably also impermeable to its absorption product(s).

[0033] Accordingly, the gas-permeable membrane of the catheter is impermeable to the CO2-absorbing carrier medium or the CO2 absorber and preferably its absorption product(s), and this also for the duration of the in vivo application.

[0034] In an alternative preferred embodiment, the gas-permeable membrane of the catheter is designed such that during the in In vivo application, the release of the CO2-absorbing carrier medium or the CO2-absorber in the gastrointestinal tract is prevented to such an extent that the concentration of the CO2-absorbing carrier medium or the CO2-absorber in the intestinal lumen is less than 1 mM, preferably less than 100 M, further preferably less than 10 µM and particularly preferably less than 1 µM.

[0035] This minimized release can also be demonstrated by a in in vitro studies are used to determine this. Both the European Pharmacopoeia (Ph. Eur.) and the American Pharmacopoeia (USP) define for in vitroDrug release studies require precise procedures and equipment. The European Pharmacopoeia specifies the equipment according to the dosage form. For example, in Chapter 2.9.3 "Drug Release from Solid Dosage Forms," ​​the following defined apparatuses are listed: rotating basket apparatus (USP); rotating paddle apparatus (USP); or flow-through cell (USP). Those skilled in the art are familiar with reaction temperatures and buffers that simulate the release of the CO₂-absorbing carrier medium or CO₂ absorber in the gastrointestinal tract. How the study must be carried out depends on the drug release profile of the dosage form, and in this case, the delayed release method will be selected.

[0036] The present formulation features a selectively permeable membrane. The selective permeability consists of the membrane being permeable to CO₂ (allowing CO₂ from the gastrointestinal tract to pass through the membrane to the CO₂-absorbing carrier medium or absorber, where it can be bound), and impermeable to the CO₂-absorbing carrier medium or absorber (whether as a CO₂-free reactant or a CO₂-containing product). The selective permeability of the present membrane persists while the catheter remains in the gastrointestinal tract. A physiologically effective amount of CO₂ is removed from the human gastrointestinal tract.

[0037] The catheter with its gas-permeable membrane of any embodiment of the invention is preferably sufficiently robust to persist in the environment of use, for example, in the GI tract or a representative thereof. in vitro To persist assays for pharmaceutical applications without significant degradation of such a catheter and / or preferably without significant deterioration of the catheter's physical and / or performance characteristics. In preferred embodiments, the gas-permeable membrane is substantially unaffected and / or possesses physical and / or performance characteristics that are maintained under physiological conditions of the GI tract (or in in vitro representations or imitations thereof) during a period of time spent in the environment of interest, such as the gastrointestinal tract, is essentially not deteriorated.

[0038] Preferably, the CO₂-absorbing carrier medium or CO₂ absorber binds the CO₂ and retains it in the environment of interest for a significant period of time. For example, in applications involving the binding of CO₂ in the gastrointestinal tract, the catheter can bind CO₂ in those areas of the gastrointestinal tract that have a relatively high concentration of CO₂. CO₂ bound in this way preferably remains bound to the CO₂-absorbing carrier medium or CO₂ absorber and is excreted from the body in a sufficient quantity to produce a therapeutically beneficial effect. Alternatively, the catheter does not release the bound CO₂ in the environment of interest, such as the gastrointestinal tract, to a significant extent before a desired therapeutic effect is achieved. The catheters described herein can retain a significant amount of CO₂.The term "significant amount," as used here, does not mean that the entire amount of bound CO₂ is retained. It is preferred that at least a large proportion of the bound CO₂ is retained so that a therapeutically relevant effect occurs.

[0039] The retention period is generally preferably the time during which the catheter is used in the area of ​​interest. For applications involving the binding of CO₂ in the gastrointestinal tract, this time is, for example, a period sufficient for a therapeutically beneficial effect. In the embodiment in which the catheter is used to bind and remove CO₂ from the gastrointestinal tract, the retention period can generally be the residence time of the composition in the gastrointestinal tract and, more preferably, the mean residence time in the small and large intestines.

[0040] Advantageously, the permeable selectivity of the catheter according to the invention is sufficiently durable to produce a beneficial effect, for example, the treatment of a respiratory system disorder. The durable selectivity (for example, the durable selective permeability) of the catheter membrane is particularly advantageous for binding CO₂ in the gastrointestinal tract.

[0041] The catheters of the invention are preferably sufficiently robust to persist in the environment of their intended use. In one application, for example, the catheters with their gas-permeable membrane are sufficiently robust to remain in the gastrointestinal system (or to persist in a representative in vitro assay) without such a catheter or its membrane undergoing significant degradation. In preferred embodiments, the gas-permeable membrane of the CO₂ absorber is preserved under physiological conditions of the gastrointestinal tract (or in in vitro Representations or imitations thereof) remain essentially robust during a period of residence in the gastrointestinal tract (for example, they are not degraded, perforated, separated, and / or delaminated). For example, the CO2 absorber and membrane under inunder vitro conditions substantially undecomposed, wherein these conditions are preferably selected from the group consisting of (ii) an aqueous solution with a pH of (about) 8 for a period of (about) 10 hours, (iii) an aqueous solution with a pH of (about) 6 for a period of (about) 20 hours and combinations thereof, each at a temperature of (about) 37°C with stirring.

[0042] In some embodiments, the CO₂-absorbing carrier medium, or preferably the particulate CO₂ absorber, can be robust with respect to aspects other than degradation, including, for example, physical characteristics and / or performance characteristics. Physical characteristics may include particle size, particle size distribution, and / or surface properties, assessed visually, for example, using microscopes such as electron microscopes and / or confocal microscopes. Performance characteristics may include specific binding capacity, selectivity (e.g., selective permeability), and durability or persistence.

[0043] Some preferred in vitroAssays that can be used in connection with determining robustness, for example for the purposes of modifying or optimizing a catheter in this respect, include the aforementioned. in vitro Drug release studies, where the CO2-absorbing carrier medium or the CO2 absorber is specifically not intended to be released as the "active ingredient".

[0044] In some embodiments, the membrane may impart other properties relating to robustness, for example, sufficient resistance to withstand mechanical forces or stresses associated with a pressurized fluid filling in connection with therapeutic application.

[0045] In embodiments of the invention, the membrane can protect the CO2-absorbing carrier media or the CO2 absorber from the external environment, for example the gastrointestinal tract.

[0046] Advantageously, the invention provides that the CO₂-absorbing carrier medium is a liquid, i.e., the carrier medium is in a liquid state during operation (under standard conditions). Due to the use of a liquid as the carrier medium, the transfer and supply of substances is significantly more controlled and efficient.

[0047] Due to the use of a liquid as the CO₂-absorbing carrier medium, the device's membrane is a liquid-compatible membrane, i.e., configured and designed for the exchange of substances between two liquids. Even though such a membrane could, or could, achieve a certain degree of substance exchange between a liquid and a gas, the overall configuration of the membrane, particularly the intended contact area and / or its mechanical stability, indicates that in one embodiment it is not designed for use with a gaseous carrier medium.

[0048] By using suitable carrier fluids and increasing the supply of this fluid, a higher CO2 uptake through the membrane can be achieved and the required membrane surface area reduced, which leads to a reduced pressure difference in the catheter and thus also allows for a reduction in the size of the delivery device.

[0049] In an embodiment which is not part of the claimed invention, the CO2-absorbing carrier medium is selected from the group consisting of: (a) a carrier liquid in which CO2 is soluble, wherein the CO2 solubility at 20 °C and 1 atm is at least 85 ml CO2 / 100 ml carrier liquid; (b) a liquid in which a CO2-adsorbing material is dissolved or dispersed; (c) a liquid in which a CO2-converting enzyme such as carbonic anhydrase is dissolved.

[0050] In one embodiment, the carrier liquid itself can serve as the CO₂-absorbing carrier medium, provided that it is a carrier liquid in which CO₂ is soluble and the CO₂ solubility at 20°C and 1 atm is at least 85 ml CO₂ / 100 ml carrier liquid. The CO₂ solubility at 20°C and 1 atm can be at least 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, or 250 ml CO₂ / 100 ml carrier liquid.

[0051] The carrier liquid with CO₂ solubility exhibits physical absorption. The term "absorption" describes the process of carbon dioxide being taken up or "dissolved" in another phase. This is not adsorption (at the surface), but rather absorption into the free volume of the absorbing phase. In physical absorption, the carbon dioxide gas dissolves in a solvent. Mixing occurs without a chemical reaction.

[0052] The blood's capacity to absorb CO₂ is approximately 20 ml / 100 ml. Carbon dioxide exists in the blood in two forms: a smaller portion is physically dissolved as free CO₂ in the blood plasma, while the larger portion is dissolved in the plasma and erythrocytes as bicarbonate, or is bound to hemoglobin in the erythrocytes (carbaminohemoglobin).

[0053] In an alternative embodiment, the CO₂-absorbing carrier medium is a liquid in which a CO₂-adsorbing material is dissolved or dispersed. Here, "adsorption" refers to the accumulation of carbon dioxide on the surface of a solid.

[0054] The device may advantageously include a CO2-adsorbing material selected from the group consisting of activated carbon, a molecular sieve such as zeolite, silica and metal-organic framework compounds (MOFs).

[0055] Activated carbon is a fine-grained carbon with a large internal surface area, which can range from 300 to 2000 m² / g. The term "molecular sieve" is used here to describe natural and synthetic zeolites or other materials that have a high adsorption capacity for carbon dioxide gas. Besides zeolites, there are also, for example, carbon molecular sieves (also known as "carbon molecular sieves" or "molecular sieving carbon"). These molecular sieves have a large internal surface area (600-700 m² / g) and uniform pore diameters, which are on the order of the diameter of molecules.Metal-organic frameworks (MOFs) are defined in the present application as microporous materials composed of inorganic building units (IBUs) and organic molecules acting as linkers between these IBUs. MOFs are coordination networks with an open framework containing pores. After synthesis, the pores of these three-dimensional structures are typically filled with guest molecules (e.g., solvents or unreacted linkers). Removing these guest molecules (e.g., by heating, vacuum, or a combination of both) allows the pores to be reopened for the uptake of gases such as CO₂.

[0056] According to the claimed invention, the CO₂-absorbing carrier medium is a liquid in which a CO₂-absorbing substance is dispersed. Absorption here refers to chemical absorption, in which the carbon dioxide undergoes a chemical reaction with the solvent or absorbent, resulting in the formation of a product substance.

[0057] For example, CO₂ can react with an inorganic hydroxide compound such as calcium hydroxide to form calcium carbonate according to the following reaction equation (I). Water is produced as a byproduct of the reaction: (I) Ca(OH)₂ (aq) + CO₂ (g) → CaCO₃ (s) + H₂O (l)

[0058] In an alternative embodiment, the CO₂-absorbing carrier medium is a liquid in which a CO₂-converting enzyme such as carbonic anhydrase is dissolved. This enzyme converts the gaseous CO₂ diffusing through the membrane into bicarbonate and hydrogen ions according to the following reaction equation (II): (II) CO₂ + 2 H₂O H₂CO₃ + H₂O H3O+< + HCO3-<

[0059] In humans, more than 10 different isoforms of α-carbonic anhydrase exist, systematically numbered with Roman numerals (CA-I, CA-II, CA-III, etc.). The zinc ion, as the active site, is responsible for the enzyme's activity. It is bound to three histidine-derived imidazole residues within the protein backbone. The fourth coordination site is occupied by a hydroxo ligand (OH-). The zinc in carbonic anhydrases is therefore tetracoordinate. A pocket for CO₂ uptake is located in close proximity.

[0060] The invention may provide that the CO₂-absorbing substance is an inorganic hydroxide compound. As a hydroxide compound, it can react with the carbon dioxide to form the corresponding carbonates. The hydroxide compound is preferably selected from lithium hydroxide, sodium hydroxide, potassium hydroxide, calcium hydroxide, and magnesium hydroxide, or mixtures thereof. The use of magnesium hydroxide is particularly preferred.

[0061] According to one embodiment, the CO₂-absorbing substance consists essentially of calcium hydroxide. The calcium hydroxide reacts with the carbon dioxide to form pharmaceutically safe calcium carbonate. Here, "essentially" means that the CO₂-absorbing substance contains at most 5 wt.%, preferably at most 4 wt.%, more preferably at most 3 wt.%, and further preferably at most 1 wt.% of other components.

[0062] In an advantageous embodiment, the calcium hydroxide-containing, CO₂-absorbing material is essentially free of sodium and potassium hydroxide. Here, "essentially" means that the CO₂-absorbing material contains at most 4 wt.%, preferably at most 2 wt.%, more preferably at most 1 wt.%, further preferably 0.5 wt.% of sodium and potassium hydroxide, and particularly preferably no sodium and potassium hydroxide.

[0063] According to a particularly preferred embodiment, the CO₂-absorbing material consists essentially of magnesium hydroxide. Magnesium hydroxide has the advantage that, due to its lower basicity, it does not cause any significant side effects even if the catheter ruptures and material leaks out.

[0064] The magnesium hydroxide reacts with the carbon dioxide to form pharmaceutically safe magnesium carbonate. "Essentially" here means that the CO₂-absorbing material contains at most 5 wt.%, preferably at most 4 wt.%, preferably at most 3 wt.%, and more preferably at most 1 wt.% of other components.

[0065] In an advantageous embodiment, the magnesium hydroxide-containing, CO₂-absorbing material is essentially free of sodium and potassium hydroxide. "Essentially" here means that the CO₂-absorbing material contains at most 4 wt.%, preferably at most 2 wt.%, more preferably at most 1 wt.%, further preferably 0.5 wt.% of sodium and potassium hydroxide, and particularly preferably no sodium and potassium hydroxide.

[0066] Advantageously, the invention may provide that the CO2 dissolving liquid is selected from the group consisting of strongly eutectic solvent, ionic liquid and perfluorocarbon.

[0067] Perfluorocarbons (PFCs) are synthetic, fully halogenated carbon compounds. In most cases, the hydrogen atoms are replaced by fluorine, but other halogens such as bromine or chlorine are also present. They can absorb and release large quantities of gases such as oxygen or carbon dioxide. Due to the very high carbon-fluorine bond energy, PFCs are chemically and metabolically inert; that is, they do not form toxic metabolites. PFCs are neither hydrophilic nor lipophilic and are immiscible with aqueous fluids such as blood. Compared to blood, PFCs have a ten times higher absorption capacity for CO₂ and thus represent a highly efficient carrier fluid for CO₂. Furthermore, PFCs have a low surface tension and spread very easily on surfaces due to their high spreading coefficient. These properties make these fluids particularly suitable for use with hollow fiber membranes.

[0068] In a preferred embodiment, the perfluorocarbon is selected from the group consisting of perfluorodecalin, perfluorodecyl bromide, perfluorooctyl bromide, perfluorodichloroctane, perfluoroisobutylcyclohexane, perfluorotributylamine and perfluoromethylcyclohexylpiperidine.

[0069] A strongly eutectic solvent can also be used as a CO₂-dissolving liquid. In the context of this application, strongly eutectic solvents (DES) are defined as multi-component, eutectic molten salts whose melting point, like that of ionic liquids, is near or below room temperature. Examples of eutectic solvents are based on a mixture of a quaternary ammonium compound with hydrogen bond donors (e.g., an amine) and a carboxylic acid.

[0070] Ionic liquids (ILs) are salts with a melting point below 100 °C. Preferably, their melting point is below 37 °C, and even more preferably below room temperature (then referred to as "room temperature ionic liquids" (RTILs)), so that they can be used in liquid form in catheters. Like all salts, they consist of anions and cations. By varying these, the physicochemical properties of an ionic liquid can be varied within wide limits and optimized for specific technical requirements. Ionic liquids are primarily used as solvents and, due to their structural diversity, are also referred to as "designer solvents."For example, 1-butyl-3-propylamino-imidazolium tetrafluoroborate is known as a CO2-absorbing ionic liquid, which, according to the following reaction scheme (III), can bind equimolar amounts of CO2 as a task-specific ionic liquid (TS-IL): .

[0071] Another example of a CO₂-storing ionic liquid is 1-butyl-3-methylimidazolium hexafluorophosphate (BMIM PF 6). With a melting point of 12°C, BMIM PF 6 is a room temperature ionic liquid (RTIL).

[0072] In one embodiment of the invention, the CO₂-absorbing carrier medium can be a gas or gas mixture, preferably having a CO₂ partial pressure of less than 40 mm Hg. For example, nitrogen or air can be introduced into the catheter as a gas mixture.

[0073] Based on a preferred use of a carrier fluid as the carrier medium, the gas-permeable membrane of the catheter is a fluid-compatible membrane, i.e., configured and set up for the exchange of substances between two fluids.

[0074] Depending on the application, i.e., in particular depending on the substance to be exchanged and thus also depending on the carrier fluid, the design, material and structure of the membrane can be adapted accordingly.

[0075] Suitable materials include, for example, hydrophilic or hydrophilized copolymers and hydrophilic polymer mixtures. Specifically, mixtures containing one or more components from a group consisting of poly(organo)siloxane, polyethylene such as high-density polyethylene (HDPE) or low-density polyethylene (LDPE), polypropylene, thermoplastic polyurethane, polyester, polybutylene succinate, polybutylene adipate terephthalate (PBAT), polyethersulfone (PES), polyaryl ethersulfone, polyacrylic ethersulfone (PAES), polyvinylpyrrolidone (PVP), polymethyl methacrylate (PMMA), polymethylpentene (PMP), polyamide (PA), polyacrylonitrile (PAN), polytetrafluoroethylene, ethylene-vinyl alcohol copolymer (EVOH), cellulose, cellulose triacetate (CTA), cellulose nitrate, and silicone-coated polypropylene can be used as membrane materials.

[0076] In one embodiment, the membrane can be a composite of a microporous PE outer layer, a PU intermediate layer and a microporous PE inner layer.

[0077] Preferably, the gas-permeable membrane comprises poly(organo)siloxane, for example in the form of a coating such as a silicone rubber-coated PE film, or, in a particularly preferred manner, the membrane consists of poly(organo)siloxane.

[0078] The pore size of the gas-permeable membrane can range between 0.01 µm and 0.1 µm.

[0079] A suitable membrane material, preferably a polymer, is used. This results in a low-risk or side-effect-free procedure. in vivo application enabled.

[0080] According to another embodiment, the membrane for providing a lubricated catheter may have one of the following properties: (a) the membrane consists of a lubricating polymer; (b) the membrane has a coating of a lubricating substance, such as water-soluble lubricating gel, PTFE or poly(organo)siloxane; (c) the membrane is coated with a lubricant before rectal insertion.

[0081] The design as a lubricated catheter facilitates rectal application and positioning in the intestinal tract and also allows the use of larger sized catheters.

[0082] Advantageously, the invention provides that the total surface area of ​​the gas-permeable membrane, which forms the contact surface for gas absorption or gas exchange, is at least 0.1 m². The contact surface area can be at least 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9 or 1.0 m².

[0083] Advantageously, the invention may provide that the gas-permeable membrane is designed as a hollow fiber membrane, wherein the inner surface of the hollow fiber membrane is in contact with the carrier medium and the outer surface of the hollow fiber membrane is in contact with the intestinal tract.

[0084] A particularly large contact area in a small space can be achieved if the membrane is a hollow fiber membrane. The actual contact area is formed by the walls of the hollow fibers or capillaries. A hollow fiber membrane can comprise up to 20,000 individual capillaries or hollow fibers. The diameter of the individual hollow fibers is between 0.01 mm and 1 mm, particularly between 0.1 and 0.5 mm.

[0085] The total surface area of ​​the membrane, which forms the contact surface for the exchange of substances, is between 0.1 and up to 10 m², preferably between 0.2 and 1 m². The material from which the hollow fibers are formed can be composed of one or more of the polymers mentioned above, with polymethylpentene or poly(organo)siloxane being preferred. In connection with the application according to the invention and optionally the conveyance of intestinal fluid through the catheter during operation, the delicate hollow fibers of the membrane can be housed in a protective catheter sheath.

[0086] The invention may provide that the catheter has a plurality of hollow fibers, wherein the fibers are each connected to the inlet via a first connection and to the outlet via a second connection, wherein the hollow fibers are preferably arranged as hollow fiber bundles and wherein the hollow fibers are arranged to a predominant extent substantially parallel to a longitudinal extension of the catheter.

[0087] According to a further embodiment, the gas-permeable membrane can be designed as an elongated hollow body with a proximal and a distal end, wherein the inner surface of the membrane is in contact with the carrier medium and an outer surface of the membrane is in contact with the intestinal tract. Due to its design as an elongated hollow body, the catheter is adapted to the shape of the intestine and allows CO₂ uptake without significantly disrupting bowel function.

[0088] The hollow body can preferably have a diameter of 3 to 8 cm and more preferably of 5 to 7 cm during operation. Operational use refers to use after positioning the catheter and the volume increase resulting from the introduction of the carrier medium. The person skilled in the art will select the diameter according to the intestinal diameter, preferably ensuring that the catheter, during use, predominantly or even completely fills the intestinal cross-section, so that maximum gas diffusion is enabled due to the small distance or, in extreme cases, the close contact between the catheter and the intestinal wall.

[0089] Advantageously, the invention provides that the inlet of the elongated hollow body is located at the distal end and the outlet at the proximal end, thus preferably defining the longest possible flow path. In this arrangement, the CO₂-absorbing carrier medium enters the hollow body through the inlet at the distal end, travels the entire length of the hollow body, and exits the hollow body through the outlet at the proximal end.

[0090] The invention may provide that the elongated hollow body has an axial length of 3 to 100 cm, preferably an axial length of 20 to 50 cm, and particularly preferably an axial length of 30 to 50 cm or 10 to 20 cm. A person skilled in the art can select a suitable length for the catheter body according to the desired uptake rate and the size of the patient.

[0091] According to another embodiment, the elongated hollow body can be provided to have one of the following shapes: (a) a tubular hollow body with a circular or oval cross-section; (b) a hollow body with longitudinally extending, substantially parallel fold or crease lines; (c) a tubular hollow body with an inner tube surrounded by an outer tube, wherein the two tubes have such different diameters that a substantially cylindrical passage is formed between the tubes through which the CO2-absorbing carrier medium can flow longitudinally; (d) a planar body with two external membrane surfaces which, together with partitions, form channels for the CO2-absorbing carrier medium, such that the membrane surfaces are in contact with the intestinal tract and wherein the membrane is arranged to allow the diffusion of gas from the intestinal tract into the channels of circulating CO2-absorbing carrier medium;or (e) a tubular hollow body which is spirally wound to form a helix, the helix preferably forming an internal channel for conveying the digestive bolus.

[0092] When designed as a tubular hollow body with a circular or oval cross-section, the catheter has a shape that is easy to implement and corresponds to the elongated intestine.

[0093] Preferably, the tubular hollow body has an internal continuous channel for conveying the digestive bolus.

[0094] Alternatively, the hollow body can be provided with longitudinally running, essentially parallel fold or crease lines, which can significantly increase the contact surface.

[0095] In a further embodiment, the device can be designed as a tubular hollow body with an inner tube, wherein the inner tube is surrounded by an outer tube, and wherein the two tubes have such different diameters that a substantially cylindrical passage is formed between the tubes, through which the CO₂-absorbing carrier medium can flow longitudinally. This ensures that the carrier medium flows in a preferably laminar flow close to the outer membrane and can thereby absorb CO₂ in an optimal manner.

[0096] In one embodiment, the hollow body is designed as a flat body with two external membrane surfaces which, together with partitions, form channels for the CO₂-absorbing carrier medium. The membrane surfaces are in contact with the intestinal environment, and the membrane is configured to allow the diffusion of gas from the intestinal environment into the CO₂-absorbing carrier medium circulating in the channels. The flat design provides a large contact surface. The specific channel configuration allows the carrier medium to be guided through the hollow body in various ways, thus enabling variable adjustment of the path length. For example, a meandering channel configuration allows for a very long path length while optimally utilizing the available contact surface.

[0097] Advantageously, the invention may provide that the catheter is movably designed in one of the following forms to increase gas diffusion: a) Rotation about the longitudinal axis; b) Alternating twisting of a hollow fiber bundle; c) Pulsating volume change.

[0098] According to one embodiment, the catheter can be designed to be expandable or dilatable, so that its cross-sectional area can increase after insertion into the intestinal tract. For example, it can be easily inserted rectally in a folded or rolled-up form and positioned in the intestine, and then expanded or dilated to its final size. This is preferably achieved by introducing the carrier medium into the catheter.

[0099] Advantageously, the invention provides that the inlet and outlet are jointly connected to the gas-permeable membrane as a double-lumen tube. The tube leading to the inlet and the tube leading to the outlet can be adjacent to each other with a semicircular cross-section in a side-by-side configuration of a larger tube, or welded together to form a tube pair. In an alternative embodiment, the two tube lumens are arranged coaxially.

[0100] According to another embodiment, the CO₂-absorbing carrier medium can be enriched with oxygen before entering the catheter, thus allowing CO₂ / O₂ gas exchange in the intestinal tract. When using a CO₂-absorbing carrier medium that also stores oxygen, the catheter can also be used for CO₂ / O₂ gas exchange. In this case, the CO₂-absorbing carrier medium must be enriched with oxygen before entering the catheter and can then both absorb CO₂ and release O₂ in the intestinal tract. This allows for the treatment of both hypercapnia and hypoxia.

[0101] The invention may provide that the catheter additionally has a sensor selected from the group consisting of CO₂ sensors, oxygen sensors, and pH sensors. Numerous embodiments of a CO₂ sensor, as well as of an oxygen sensor or pH sensor, are known to those skilled in the art. By measuring the CO₂ content, the catheter's uptake rate can be adjusted, for example, by increasing or decreasing the flow rate. When using metal hydroxides, the extent of the pH change is a measure of the CO₂ uptake rate, which can therefore be easily determined by measuring the pH value.

[0102] The invention may provide that the catheter additionally has a flushing tube with an outlet opening into the intestinal tract, the outlet opening preferably being located at or near the proximal end. This allows the intestine to be flushed during treatment and thus optimizes gas exchange.

[0103] In a preferred embodiment, the catheter is designed as a disposable item. It is advantageous if the catheter consists of a sealed hollow body and is discarded after therapeutic use, as a single-use product.

[0104] Advantageously, the invention provides that the inlet is connected to a container for the CO₂-absorbing carrier fluid and to a pump for transporting the CO₂-absorbing carrier fluid from the container to the catheter, and that the outlet is preferably connected to a collection container for receiving the CO₂-absorbing carrier fluid. In this simplest conveying configuration, the CO₂-absorbing fluid, present in a container serving as a reservoir, is pumped by means of a pump through a first fluid line and the inlet into the catheter and, after CO₂ absorption, is directed at the outlet side through a second fluid line into the collection container.

[0105] According to a further embodiment, the catheter can be connected to an extracorporeal exchange device to form a circulating system, wherein the circulating system includes a pump for conveying the carrier medium, and preferably a first switching device is additionally provided in the circulating system, by means of which the carrier medium flowing from the catheter is selectively returned to the catheter or directed to the collection container. In this embodiment, there are thus two fluid paths side by side. First, a unidirectional path according to the previous embodiment, and second, a circulating system, wherein the two fluid paths can be supplied alternatively by a switching device. Thus, the carrier medium can initially circulate in the circulating system until the desired CO₂ uptake quantity (possibly(even up to CO2 saturation) has taken place, in order to then be diverted into the collection container, in order to then subsequently fill the catheter with new carrier medium.

[0106] A flexible hose is conveniently used as the liquid line, which is also referred to as a hose line in the following.

[0107] Those skilled in the art are well aware of pumps from the field of catheters, which they can select appropriately to match the required flow rate and delivery volume. The invention may provide that the pump is selected from the group consisting of peristaltic pumps, pulsion pumps, centrifugal pumps, diaphragm pumps, and piston pumps, with a peristaltic pump or a centrifugal pump being preferred.

[0108] Advantageously, the invention may provide that the device is additionally equipped with a control device which controls the supply or circulation of the CO2-absorbing carrier medium in the catheter, preferably on the basis of the CO2 absorption rate of the carrier medium.

[0109] According to a further embodiment, the device may additionally include an insertion aid for rectal insertion of the catheter into the intestinal tract. For example, a sleeve with a cavity may be used, the cavity being suitable for receiving the catheter.

[0110] After inserting the sleeve and positioning it at the desired section of the intestine, the sleeve can be withdrawn, leaving the catheter in place. The catheter is preferably empty or folded and, after positioning, expands to its final size by filling it with the carrier medium.

[0111] Alternatively, the device can also have a guide wire that is permanently or reversibly detachably connected to the catheter.

[0112] In a further embodiment, the device can also include a receiving device for an endoscope as an insertion aid. In a second aspect, the invention relates to a set comprising the catheter according to the invention, a pump, an exchange device and a hose connected to the catheter and the pump or exchange device for transporting a carrier fluid between the catheter and the pump or exchange device.

[0113] In a third aspect, the invention relates to the device or set according to the invention for use in the prophylaxis or treatment of diseases of the respiratory system such as acute or chronic respiratory diseases or lung diseases; of cardiovascular diseases, metabolic disorders such as ketoacidosis, or of infectious diseases or respiratory disorders after severe illness.

[0114] In the prophylaxis or treatment of respiratory system diseases, the patient subgroup of those with diverticulosis can also be advantageously treated. Diverticulosis involves the presence of one or more balloon-like pouches (diverticula), usually in the large intestine (colon). Since the catheter according to the invention is securely positioned as a single device within the intestinal lumen, patients with diverticulosis do not represent a contraindication for treatment according to the third aspect of the invention, and this patient subgroup can be treated safely and effectively with the device according to the invention. This is particularly important in emergency treatment, as a differential diagnosis for the presence of diverticula is not required beforehand.

[0115] Advantageously, the invention may provide that the disease of the respiratory system is selected from the list consisting of: (a) chronic obstructive pulmonary disease; (b) asthma; (c) cystic fibrosis; (d) acute respiratory failure; (e) hypercapnia; (f) pneumonia; (g) lung cancer; (h) pulmonary fibrosis; (i) respiratory diseases following medical intervention as defined in ICD-10 J95; (j) respiratory failure as defined in ICD-10 J96; (k) other respiratory diseases as defined in ICD-10 J97; (l) respiratory diseases associated with diseases classified elsewhere as defined in ICD-10 J99; or (m) immature lung.

[0116] In the prophylaxis or treatment of diseases of the respiratory system according to points (a) to (m), the patient subgroup of patients with diverticulosis can also be treated as previously described.

[0117] In another aspect, the invention relates to the device or set according to the invention for use in the induction of hypocapnia in a patient.

[0118] When inducing hypercapnia in a patient, the patient subgroup of patients with diverticulosis can also be treated, as previously described.

[0119] The invention may provide that its use includes the following steps: (a) optional chemical or mechanical partial degradation of the intestinal mucosal barrier to increase gas diffusion through the intestinal epithelium and / or bowel emptying by means of a levee-lowering enema; (b) rectal insertion of the catheter according to the invention for positioning in the lumen of the intestinal tract, preferably in the descending colon; (c) extracorporeal supply of CO2-absorbing carrier medium into the lumen of the catheter for absorption of CO2 from the intestinal tract; (d) optional circulation of the CO2-absorbing carrier medium in a circulatory system with an extracorporeal exchange device until the carrier medium, as the spent carrier medium, has a predetermined CO2 content; (e) drainage of the spent carrier medium from the catheter into a collection container.

[0120] When using this method, the CO2-absorbing carrier medium can preferably be passed through the catheter at a flow rate of 1 to 5 L / min in step (c) and / or step (d).

[0121] Advantageously, the CO₂-absorbing carrier medium contains a pH indicator. When using metal hydroxides, the extent of the pH change is a measure of the CO₂ uptake rate, so the uptake rate can be easily determined by measuring the pH value. Definitions

[0122] In this document, the term "polymer" encompasses, on the one hand, a group of chemically uniform macromolecules that differ in degree of polymerization, molar mass, and chain length, and which are produced by a polymerization reaction (polymerization, polyaddition, polycondensation). On the other hand, the term also includes derivatives of such a group of macromolecules from polymerization reactions; that is, compounds obtained by changes, such as additions or substitutions, of functional groups on given macromolecules, and which may be chemically uniform or chemically heterogeneous. Furthermore, the term includes copolymers and so-called prepolymers, that is, reactive oligomeric pre-adducts whose functional groups are involved in the construction of macromolecules.

[0123] In this document, the term "copolymer" refers to a polymer composed of two or more different types of monomer units. This distinguishes a copolymer from a homopolymer, which consists of only one (real or imagined) type of monomer and therefore has only one repeating unit. Copolymers can be divided into five classes, namely: 1.) Statistical copolymers, in which the distribution of the two monomers in the chain follows a statistical distribution; 2.) Gradient copolymers, which are similar in principle to statistical copolymers, but in which the proportion of one monomer increases and that of the other decreases along the chain; 3.) Alternating copolymers, in which the two monomers alternate; 4.) Block copolymers and segment copolymers, which consist of longer sequences or blocks of each monomer; and 5.) Graft copolymers, in which blocks of one monomer are grafted onto the backbone of another monomer.

[0124] In this document, the term "solvent" refers to compounds as listed as organic solvents in CD Römpp Chemie Lexikon, 9th edition, version 1.0, Georg Thieme Verlag, Stuttgart 1995. The polyols used according to the invention are not covered by this definition, although they act as solvents for the monomers and also for the low-molecular-weight polymer produced by radical polymerization.

[0125] In this document, "liquid" refers to substances that can be deformed and are flowable, which also includes highly viscous and pasty substances.

[0126] The term hypercapnia according to the present invention describes an increase in the arterial CO2 partial pressure above 45 mm Hg, and thus characterizes a pathologically increased CO2 concentration in the blood.

[0127] The causes of an increase in the partial pressure of carbon dioxide are generally due to respiratory pump failure, as seen, for example, in respiratory insufficiency with hypoventilation and resulting respiratory acidosis. Classic examples include airway obstruction caused by a retracted tongue, as well as breathing obstructed by mucus and blood. Other causes of hypercapnia include drug effects (muscle relaxant excess, opiates, hypnotics), impaired respiratory mechanics due to pneumothorax, or impaired gas exchange due to pulmonary edema. Symptoms of hypercapnia are primarily impaired consciousness and possibly coma (a severe increase is also referred to as "carbon dioxide narcosis").

[0128] The term "hypocapnia" describes the opposite of hypercapnia, namely a decrease in the arterial partial pressure of CO₂, or a reduced CO₂ concentration, for example, due to hyperventilation. This results in respiratory alkalosis. Furthermore, hypocapnia can also occur as a consequence of respiratory compensation for metabolic alkalosis. Cardiocirculatory effects of hypocapnia include an increase in peripheral vascular resistance, a decrease in cardiac output, an increase in coronary resistance, and a decrease in coronary blood flow.

[0129] It should be expressly noted that, within the context of this patent application, indefinite articles and indefinite numerical expressions such as "one...", "two...", etc., are generally to be understood as minimum values, i.e., "at least one...", "at least two...", etc., unless the context or the specific text of a particular passage indicates that only "exactly one...", "exactly two...", etc., is meant. Furthermore, all numerical values, as well as information on process parameters and / or device parameters, are to be understood in a technical sense, i.e., as being subject to the usual tolerances. Even the explicit inclusion of the limitation "at least" or "at least" or similar should not be interpreted as meaning "exactly one" when simply using "one," i.e., without the inclusion of "at least" or similar.

[0130] Unless otherwise stated, the percentages in this document refer to weight percentages.

[0131] The embodiments shown here are merely examples of the present invention and should therefore not be interpreted as limiting. Alternative embodiments considered by a person skilled in the art are likewise covered by the scope of protection of the present invention. Examples of implementation

[0132] Various embodiments of the invention are described below with reference to the illustrations. They show: Fig. 1 Schematic representation of a catheter according to the invention designed as a hollow body Fig. 2 Schematic representation of a catheter designed as a hollow body according to the invention in sectional view with proximal inlet and distal inlet Fig. 3 Schematic representation of a catheter according to the invention comprising a hollow fiber membrane. Fig. 4Schematic representation of a catheter according to the invention in sectional view with meandering channels; as well as Fig. 5 in a schematic hand-sketched representation a catheter and Fig. 6 whose use in the intestinal tract.

[0133] Figure 1 Figure 10 shows the device with the catheter 20 as an essential component, which is cylindrical and enclosed by the gas-permeable membrane 60. The catheter has an inlet 30 at its lower end for supplying the CO2-absorbing carrier medium and an outlet 40 at its upper end for removing the CO2-absorbing carrier medium after absorption of the CO2 from the intestinal environment.

[0134] Figure 2Figure 1 shows a further embodiment of a catheter 20 according to the invention in cross-section, in which the gas-permeable membrane 60 forms an elongated hollow body with rounded ends and the membrane is in contact with the carrier medium located in the lumen 70 on a first side 90 and with the intestinal environment on a second side 80, thereby allowing the diffusion of gas from the intestinal tract into the CO₂-absorbing carrier medium. The catheter has an inlet 30 at the upper end for supplying the CO₂-absorbing carrier medium and an outlet 40 at the lower end for removing the CO₂-absorbing carrier medium after absorption of the CO₂ from the intestinal environment.

[0135] Figure 3The device 10 shows the catheter 20 as an essential component, which has a plurality of hollow fiber membranes 60a through which a carrier medium can flow internally, and which are in contact with the intestinal environment via their outer surface. The catheter has an inlet 30 at its lower end for supplying the CO2-absorbing carrier medium and an outlet 40 at its upper end for removing the CO2-absorbing carrier medium after absorption of the CO2 from the intestinal environment.

[0136] Figure 4Figure 1 shows the device with the catheter 20 as an essential component, which is designed as a flat body and is enclosed, at least on its flat sides, by the gas-permeable membrane 60. The flat body has meandering channels 100 through which the carrier medium is guided. The catheter has an inlet 30 at its lower left end for supplying the CO₂-absorbing carrier medium and an outlet at its lower right end for removing the CO₂-absorbing carrier medium after it has absorbed the CO₂ from the intestinal environment.

[0137] Figure 5Figure 1 shows a cross-sectional embodiment of a catheter 20 according to the invention, in which the gas-permeable membrane 60 forms an elongated, pouch-shaped hollow body and the membrane is in contact with the carrier medium located in the lumen 70 on a first side 90 and with the intestinal environment on a second side 80, thereby allowing the diffusion of gas from the intestinal tract into the CO₂-absorbing carrier medium located in the lumen. The catheter is connected at its distal lower end to a first supply line 110, which has a proximal inlet 30 (i.e., located at the upper end) for supplying the CO₂-absorbing carrier medium. The catheter is also connected at its distal lower end to a second supply line 120, which has a distal inlet 30 (i.e., located at the upper end) for supplying the CO₂-absorbing carrier medium.has an outlet 40 located at the lower end for the removal of the CO2-absorbing carrier medium after absorption of the CO2 from the intestinal environment.

[0138] Figure 6 schematically illustrates the therapeutic application of the in Figure 5The catheter is shown. After rectal insertion, the catheter is positioned in the large intestine and rectum 130 and is connected via the inlet tube 110 to a pump and a reservoir for the CO₂-absorbing carrier medium (not shown). The catheter is also connected via the outlet tube 120 to a disposal container (not shown). During therapeutic use, the pump delivers the CO₂-absorbing carrier medium via the tube 110 into the catheter, where it enters the catheter at the proximal inlet and absorbs carbon dioxide through the membrane bag as it flows through. The CO₂-enriched carrier medium exits the catheter at the proximal end via the outlet and is disposed of via the outlet tube 120 in the collection container. Reference symbol list

[0139] 10 Device 20 Catheter 30 Inlet 40 Outlet 50 Carrier medium 60 Gas-permeable membrane 60a Gas-permeable hollow fiber membrane 70 Lumen 80 Outer surface of the membrane - contact with intestinal environment 90 Inner surface of the membrane - contact with carrier medium 100 Meandering channels 110 Intake tube 120 Drainage tube 130 Large intestine and rectum

Claims

1. A device for enterally capturing CO2 comprising a catheter for use in the intestinal tract, wherein the catheter comprises - an inlet and - an outlet for a CO2-capturing carrier medium and - a gas-permeable membrane, wherein ∘ the membrane defines a lumen for capturing the CO2-capturing carrier medium, ∘ wherein a first, inner side of the membrane is directed towards the lumen such that it is in contact with the carrier medium when the lumen is filled with the CO2-capturing carrier medium, and ∘ a second, outer side of the membrane is directed towards an environment such that it is in contact with the intestinal environment when positioned in an intestine, ∘ wherein the membrane comprises a gas passage from the outer to the inner side such that the membrane allows diffusion of gas from the intestinal tract into the CO2-capturing carrier medium when positioned in the intestinal environment and wherein the catheter is filled with the CO2-capturing carrier medium, characterized in that the CO2-capturing carrier medium is a liquid in which a CO2-absorbing substance is dispersed, and that the inlet and outlet are separate accesses.

2. The device according to claim 1, characterized in that the gas-permeable membrane is impermeable to water and / or has a molecular weight cutoff (MWCO) of less than 200 daltons.

3. The device according to claim 1 or 2, characterized in that the CO2-absorbing substance comprises an inorganic hydroxide compound, which is preferably selected from lithium hydroxide, sodium hydroxide, potassium hydroxide, calcium hydroxide and magnesium hydroxide or mixtures thereof, and more preferably is magnesium hydroxide.

4. The device according to any of the preceding claims, characterized in that the gas-permeable membrane comprises a polymer selected from the group consisting of poly(organo)siloxane, polyethylene such as high-density polyethylene (HDPE) or low-density polyethylene (LDPE), polypropylene, thermoplastic polyurethane, polyester; polybutylene succinate; polybutylene adipate terephthalate (PBAT), polyethersulfone (PES), polyarylethersulfone, polyacrylethersulfone (PAES), polyvinylpyrrolidone (PVP), polymethylmethacrylate (PMMA), polyamide (PA), polyacrylonitrile (PAN), ethylenevinyl alcohol copolymer (EVOH), polytetrafluoroethylene, cellulose, cellulose triacetate (CTA), polymethylpentene (PMP), cellulose nitrate and silicone-coated polypropylene and mixtures thereof, wherein poly(organo)siloxane is more preferred.

5. The device according to any of the preceding claims, characterized in that the membrane comprises one of the following properties for providing a slidable catheter: (a) the membrane consists of or comprises a slidable polymer; (b) the membrane comprises a coating of a slidable substance, such as Vaseline, water-soluble sliding gel, PTFE or poly(organo)siloxane; or (c) the membrane is provided with a lubricant for rectal insertion.

6. The device according to any of the preceding claims, characterized in that the total surface area of the gas-permeable membrane, which forms the contact surface for gas capture or gas exchange, is at least 0.1 m2.

7. The device according to any of the preceding claims, characterized in that the gas-permeable membrane is formed as a hollow fiber membrane, wherein the inner surface of the hollow fiber membrane is in contact with the carrier medium and the outer surface of the hollow fiber membrane is in contact with the intestinal tract, wherein the hollow fiber preferably has a diameter of less than 1 mm.

8. The device according to claim 7, characterized in that the catheter comprises a plurality of hollow fibers, wherein the fibers are each connected with a first connection to the inlet and a second connection to the outlet, wherein the hollow fibers are preferably present as hollow fiber bundles and wherein the hollow fibers are arranged for the most part substantially parallel to a longitudinal extension of the catheter.

9. The device according to any of claims 1 to 6, characterized in that the gas-permeable membrane is formed as an elongated hollow body with a proximal and a distal end, wherein the inner surface of the membrane is in contact with the carrier medium and an outer surface of the membrane is in contact with the intestinal tract, wherein the hollow body preferably has a diameter of 3 to 8 cm and further preferably of 5 to 7 cm in operation; and / or wherein the inlet at the distal end and the outlet at the proximal end are attached to the elongated hollow body such that they define a flow path.

10. The device according to any of claims 1 to 6 or 9, characterized in that the catheter formed as an elongated hollow body comprises one of the following configurations: (a) a tubular hollow body with a circular or oval cross-section; wherein this tubular hollow body preferably comprises an inner continuous channel for conveying the digestive pulp; (b) a hollow body with substantially parallel fold or bend lines running on the longitudinal side; (c) a tubular hollow body with an inner tube which is surrounded by an outer tube, wherein the two tubes have a different diameter such that a substantially cylindrical passage is formed between the tubes, through which passage the CO2-capturing carrier medium can flow on the longitudinal side; (d) a planar body with two outer membrane surfaces which together with intermediate walls form channels for the CO2-capturing carrier medium such that the membrane surfaces are in contact with the intestinal environment and wherein the membrane is adapted such that it allows diffusion of gas from the intestinal environment into the CO2-capturing carrier medium circulating in the channels; or (e) a tubular hollow body which forms a helically wound helix, wherein the helix preferably comprises an inner channel for conveying the digestive pulp.

11. The device according to any of the preceding claims, characterized in that the inlet is fluidically connected to a container for the CO2-capturing carrier liquid and to a pump for transporting the CO2-capturing carrier liquid from the container to the catheter and the outlet is preferably fluidically connected to a collecting container for capturing the CO2-capturing carrier medium.

12. The device according to any of the preceding claims, characterized in that the catheter is connected to an extracorporeal exchange device for forming a circulation system, wherein the circulation system comprises a pump for conveying the carrier medium, and preferably a first switching device is additionally provided in the circulation system, with the aid of which the carrier medium flowing out of the catheter is optionally returned to the catheter or can be fed to the collecting container.

13. A kit comprising a device according to claim 11 or 12 and a tube connected to the catheter and the pump or exchange device for transporting a carrier liquid between the catheter and the pump or exchange device.

14. The device according to claim 11 or 12 or a kit according to claim 13 suitable for use in the prophylaxis or treatment of diseases of the respiratory system such as acute or chronic respiratory diseases or pulmonary diseases; of cardiovascular diseases, metabolic derailments such as, for example, ketoacidosis, or of infectious diseases or disorders of respiration following severe courses of disease, preferably for use in the induction of hypocapnia in a patient.

15. The device according to claim 14, characterized in that the use comprises the following steps: (a) optional chemical or mechanical partial degradation of the mucosa barrier of the intestine for increasing the gas diffusion through the intestinal epithelium and / or emptying of the intestine through a raising-lowering inlet; (b) rectal insertion of a catheter according to any of claims 1 to 10 for positioning in the lumen of the intestinal tract, preferably of the colon descendent; (c) extracorporeal supply of CO2-capturing carrier medium into the lumen of the catheter for capturing CO2 from the intestinal tract, at air preferably 1 to 5 liters / minute, with a MgOH2 suspension preferably around 1 ml / minute; (d) optional circulation of the CO2-capturing carrier medium in a circulation system with extracorporeal exchange device until the carrier medium has a predetermined CO2 content as used carrier medium; (e) discharge of the used carrier medium from the catheter into a collecting container.